| Calreticulin mutants as oncogenic rogue chaperones for TpoR and traffic-defective pathogenic TpoR mutants C Pecquet, I Chachoua, A Roy, T Balligand, G Vertenoeil, E Leroy, ... Blood, The Journal of the American Society of Hematology 133 (25), 2669-2681, 2019 | 90 | 2019 |
| Molecular identification of hydroxylysine kinase and of ammoniophospholyases acting on 5-phosphohydroxy-L-lysine and phosphoethanolamine M Veiga-da-Cunha, F Hadi, T Balligand, V Stroobant, E Van Schaftingen Journal of Biological Chemistry 287 (10), 7246-7255, 2012 | 62 | 2012 |
| Pathologic activation of thrombopoietin receptor and JAK2-STAT5 pathway by frameshift mutants of mouse calreticulin T Balligand, Y Achouri, C Pecquet, I Chachoua, H Nivarthi, C Marty, ... Leukemia 30 (8), 1775, 2016 | 53 | 2016 |
| Knock-in of murine Calr del52 induces essential thrombocythemia with slow-rising dominance in mice and reveals key role of Calr exon 9 in cardiac development T Balligand, Y Achouri, C Pecquet, G Gaudray, D Colau, E Hug, ... Leukemia 34 (2), 510-521, 2020 | 40 | 2020 |
| Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy C Pecquet, T Balligand, I Chachoua, A Roy, G Vertenoeil, D Colau, ... Blood 132 (Supplement 1), 4-4, 2018 | 36 | 2018 |
| Differential effect of inhibitory strategies of the V617 mutant of JAK2 on cytokine receptor signaling E Leroy, T Balligand, C Pecquet, C Mouton, D Colau, AK Shiau, A Dusa, ... Journal of Allergy and Clinical Immunology 144 (1), 224-235, 2019 | 20 | 2019 |
| New pathogenic mechanisms induced by germline erythropoietin receptor mutations in primary erythrocytosis F Pasquier, C Marty, T Balligand, F Verdier, S Grosjean, V Gryshkova, ... haematologica 103 (4), 575, 2018 | 18 | 2018 |
| Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms C Pecquet, N Papadopoulos, T Balligand, I Chachoua, A Tisserand, ... Blood 141 (8), 917-929, 2023 | 14 | 2023 |
| Hematoxylin binds to mutant calreticulin and disrupts its abnormal interaction with thrombopoietin receptor R Jia, T Balligand, V Atamanyuk, H Nivarthi, E Xu, L Kutzner, J Weinzierl, ... Blood, The Journal of the American Society of Hematology 137 (14), 1920-1931, 2021 | 8 | 2021 |
| Crispr/Cas9 engineered 61bp deletion in the Calr gene of mice leads to development of thrombocytosis T Balligand, Y Achouri, I Chachoua, C Pecquet, JP Defour, ... Blood 128 (22), 4274, 2016 | 6 | 2016 |
| An armed anti-immunoglobulin light chain nanobody protects mice against influenza A and B infections X Liu, T Balligand, C Carpenet, HL Ploegh Science Immunology 8 (84), eadg9459, 2023 | 3 | 2023 |
| Constitutive activation and oncogenicity are mediated by loss of helical structure at the cytosolic boundary of thrombopoietin receptor mutant dimers JP Defour, E Leroy, S Dass, T Balligand, G Levy, IC Brett, ... Elife 12, e81521, 2023 | 3 | 2023 |
| JAK2 V617F dimerizes homodimeric cytokine receptors cytosolic domains by requiring pseudokinase domain residues that promote JAK2 dimerization and oncogenic activity E Leroy, T Balligand, SN Constantinescu Blood 132, 50, 2018 | 2 | 2018 |
| The thrombopoietin receptor supports prolonged Jak2 V617f dimerization and activation and is more sensitive to low Jak2 V617f levels due to long half-life when compared to Epor … V Gryshkova, T Balligand, S Najjar, SN Constantinescu Haematologica 100, 327, 2015 | 2 | 2015 |
| Disease Phenotype and Clonal Amplification in Calreticulin del52 and ins5 Knock-in Mice Are Dependent on the Type of Mutations and Gene Dosage C Benlabiod, M da Costa Cacemiro, T Balligand, B Panneau-Schmaltz, ... Blood 134, 311, 2019 | 1 | 2019 |
| Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors ER Verhaar, WJC van Keizerswaard, A Knoflook, T Balligand, HL Ploegh PNAS Nexus, pgae184, 2024 | | 2024 |
| Mouse models of myeloproliferative neoplasms identifying oncogenic and hematopoiesis dominance functions of mutated calreticulins T Balligand UCL-Université Catholique de Louvain, 2019 | | 2019 |
| Pathological activation of TpoR and JAK2 STAT5 pathway by frameshift mutants of murine calreticulin T Balligand, Y Achouri, C Pecquet, I Chachoua, H Nivarthi, C Marty, ... Belgian Medical Genomics Initiative Symposium, 2016 | | 2016 |
| PHENOTYPIC VARIABILITY IN A FAMILY WITH X-LINKED RETINITIS PIGMENTOSA: WHEN THE EYES GO WRONG, LOOK AT THE CILIA! T Balligand, K Dahan, JP Lengele Acta Clinica Belgica 68, 462, 2013 | | 2013 |
